BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996)

Leukemia

Volumn 16, Issue 6, 2002, Pages 1099-1111

  Kamps, W A ^a,b   Bokkerink J P M ^a,c   Hakvoort Cammel, F G A J ^a,d   Veerman, A J P ^a,e   Weening, R S ^a,f   Van Wering, E R ^a   Van Weerden, J F ^a   Hermans, J ^a,g   Slater, R ^h,i   Van den Berg, E ^i,j   Kroes, W G ^i,k   Does van den Berg, A ^a  

^a Dutch Childhood Leukemia Study Group   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ Dutch Workgroup on Cancer Genetics and Cytogenetics (NWKGC)   (Netherlands)

^j UNIVERSITY OF GRONINGEN   (Netherlands)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

Acute childhood leukemia; BFM oriented treatment; Children; High dose 6 mercaptopurine; High dose L asparaginase

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLAST CELL; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INFANT; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKULL IRRADIATION; TREATMENT FAILURE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BRAIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NETHERLANDS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85014276234     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402489     Document Type: Article

References (41)

1. Therapy results in five ALL-BFM studies since 1970. Complications of risk factors for prognosis
2. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: Results of DCLSG Protocol ALL-7 (1988-1991)
3. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
4. The treatment of childhood acute lymphoblastic leukemia
5. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: Results of the randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia the Associazione Italiana Ematologia Oncologia Pediatrica
6. Minimal requirements for the diagnosis, classification and evaluation of the treatment of childhood ALL in the 'BFM Family' Cooperative Group
7. Storage of cerebrospinal fluid samples at room temperature
8. Diagnosis of meningeal involvement in childhood acture lymphoblastic leukemia: Cytomorphology and TdT
9. Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindersalter: Prognostische Bedeutung und praktische Anwendung
10. Contribution of electronmicroscopy to the classification of the minimally differentiated leukemias in children
11. Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study Group
12. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
13. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AEIOP-ALL91 study
14. Spotlight on long-term results of pediatric ALL clinical trials from 12 study groups worldwide
15. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with lymphoblastic leukemia
16. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features; a Childrens Cancer Group phase III Trial
17. Long term results of three randomized trials (58831, 58832 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report
18. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype
19. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone
20. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01
21. Treatment of childhood acute lymphoblastic leukemia: Long-term results of the AIEOP-ALL 87 study
22. Comparative pharmacokinetic studies of three asparaginase preparations
23. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
24. Gender and treatment outcome in childhood Olymphoblastic leukemia: Report from the MRC UKALL trials
25. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study
26. Sex differences in prognosis for children with acute lymphoblastic leukemia
27. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells
28. 6-Mercaptopurine cumulative dose. A critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia
29. Results and significance of six randomized trials in four consecutive ALL-BFM studies
30. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
31. Cytoreduction and prognosis in acute lymphoblastic leukaemia. The importance of early marrow response
32. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
33. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
34. Variable mercaptopurine metabolism in children with leukaemia: A problem of non-compliance?
35. High cure rate with a moderately intensive treatment regiment in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group
36. Long-term follow up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991
37. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood
38. Avascular osteonecrosis as side effect of treatment in childhood ALL may not be dependent upon dexemethasone dose